根据提供的文档内容，该文本主要为免责声明和风险提示，不包含具体的公司或行业信息，因此无法提取与公司或行业相关的关键要点

公司介绍 - Invesco是一家独立的投资管理公司 致力于为客户提供投资体验 帮助人们获得更好的生活 [1] - 公司提供专家投资观点 通过Invesco US Blog发布 投资者可第一时间获取 [1] 业务范围 - Invesco Distributors Inc 是Invesco Ltd零售产品和集合信托基金的美国分销商 [1] - Invesco Advisers Inc 和其他附属投资顾问提供投资咨询服务 不销售证券 [1] - Invesco单位投资信托由发起人Invesco Capital Markets Inc和包括Invesco Distributors Inc在内的经纪交易商分销 [1] 品牌信息 - PowerShares®是Invesco PowerShares Capital Management LLC的注册商标 [1] - 上述实体都是Invesco Ltd的间接全资子公司 [1]

SET to Advance Capital Market Infrastructure with Nasdaq’s Risk and Surveillance TechnologyNEW YORK and BANGKOK, May 13, 2025 (GLOBE NEWSWIRE) -- The Stock Exchange of Thailand (SET) and Nasdaq (Nasdaq: NDAQ) today announced an expanded strategic technology partnership aimed at modernizing Thailand’s capital markets. The collaboration focuses on strengthening market resilience and integrity while aligning with global standards and leveraging Nasdaq’s AI capabilities. SET will promote the adoption of Nasdaq’ ...

MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases which has transitioned to a developer and distributor of diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), H. pylori and HCC, today announced that on May 9, 2025, the Company received wr ...

Positions American Bitcoin to become a publicly traded vehicle for low-cost Bitcoin accumulation at scaleMIAMI, May 12, 2025 /PRNewswire/ -- American Bitcoin Corp. ("American Bitcoin" or the "Company"), a Bitcoin accumulation platform focused on building America's Bitcoin infrastructure backbone, today announced that it has entered into a definitive merger agreement with Gryphon Digital Mining, Inc. (Nasdaq: GRYP) ("Gryphon") pursuant to which Gryphon will acquire American Bitcoin in a stock-for-stock merge ...

It's not too late to buy into these beaten-down tech giants.In case you missed it, tech stocks are rallying again.After hitting an all-time high in December, the Nasdaq Composite index fell in January as DeepSeek upended the artificial intelligence (AI) universe with breakthroughs in training and inference efficiency. By late February, many feared that some of the biggest names in tech could be hit hard by President Donald Trump's tariffs. The sell-off accelerated in April after the global tariffs Trump ann ...

文章核心观点 2025年5月19日周一开盘前Shopify将取代MongoDB成为纳斯达克100指数及相关指数成分股 [1][2] 分组1：指数调整信息 - Shopify将在2025年5月19日周一开盘前成为纳斯达克100指数和纳斯达克100等权重指数成分股并取代MongoDB [1] - 同日MongoDB将从纳斯达克100科技板块指数等多个指数中移除Shopify将在部分指数中取代MongoDB [2] 分组2：公司介绍 - Nasdaq是服务企业客户等的全球领先科技公司旨在提供改善全球经济流动性等的平台 [4] - 可访问https://www.shopify.com/获取Shopify公司更多信息 [3] 分组3：联系方式 - 媒体联系人为Maximilian Leitenberger邮箱为Maximilian.Leitenberger@nasdaq.com [6] - 发行人及投资者联系Index Client Services邮箱为Indexservices@nasdaq.com [6]

公司动态 - Femto Technologies Inc收到纳斯达克通知 因2025年2月26日完成的私募配售交易导致大量权证现金行权及"替代行权"股份发行 引发显著股东稀释 触发纳斯达克5101条款下的退市决定 [1][2] - 公司计划依据5800系列规则向听证委员会提出上诉 听证请求将使股票暂停交易状态维持至委员会裁决 [3] 业务与技术 - Femto Technologies Inc为前沿女性科技公司 专注AI驱动的健康技术解决方案 通过智能技术整合提升健康水平 [4] - 核心产品Sensera采用专有智能释放系统技术 结合机器学习与AI 获CES 2025创新奖AI类别荣誉 定位女性健康与愉悦需求 [5] 公司信息 - 公司原名为BYND Cannasoft Enterprises Inc 纳斯达克代码FMTO 首席财务官联系方式已披露 [4][7] - Sensera产品官网及社交媒体渠道信息完整 [6]

文章核心观点 截至2025年4月30日结算日，纳斯达克证券的卖空兴趣较上一报告期有所增加 [1][2][3] 各市场卖空兴趣情况 纳斯达克全球市场 - 2025年4月30日结算日，3156只纳斯达克全球市场证券的卖空股数达133.00707903亿股，4月15日为132.11633004亿股 [1] - 4月中旬卖空兴趣代表2.40天，上一报告期为1.76天 [1] 纳斯达克资本市场 - 2025年4月30日结算日，1636只纳斯达克资本市场证券的卖空股数达26.45060429亿股，上一报告期为26.09354721亿股 [2] - 代表1.00天的日均成交量，与上一报告期持平 [2] 纳斯达克全部证券 - 2025年4月30日结算日，4792只纳斯达克证券的卖空股数达159.45768331亿股，上一报告期为4777只证券的158.20987725亿股 [3] - 为1.92天的日均成交量，上一报告期平均为1.52天 [3] 卖空相关定义 - 每只纳斯达克证券报告的未平仓卖空头寸反映所有经纪/交易商卖空的股票总数，卖空通常指卖方出售并不持有的证券或通过交付为卖方账户借入的证券完成的出售 [4] 公司介绍 - 纳斯达克是一家领先的全球科技公司，为企业客户、投资经理、银行、经纪商和交易所运营商服务，致力于提供改善全球经济流动性、透明度和诚信度的平台 [7]

CAMBRIDGE, Mass., May 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) ("MetaVia"), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a private placement that MetaVia estimates will result in gross proceeds of approximately $10.0 million, before deducting the placement agent's fees and other offering expenses payable by the company. MetaVia currently intends to use the net proceeds from the offering for working capital and corporate purposes, includi ...